CGTN
11.6.2020 17:14:08 CEST | Business Wire | Press release
The novel coronavirus has so far claimed over 400,000 lives worldwide, according to John Hopkins University. No one knows how dangerous the virus really is and how long the pandemic will last.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200611005636/en/
To present readers with a clear picture of how we got here, CGTN portrayed seven* hard-hit countries in an interactive Super Virus . These countries – China, South Korea, the U.S., Germany, France, Italy and the UK – all reported initial confirmed cases at an early stage of the outbreak and all have their relatively mature healthcare systems strained in the fight against it. But their different policy measures have resulted in varied outcomes.
While it’s far too early to draw simple conclusions, the policy measures taken in each country do require scrutiny. The interactive takes a comparative approach in visualizing when and how quickly these measures were enacted over the course of the pandemic. CGTN compiled and analyzed data in the realms of testing, which is crucial to early detection, preventive measures including economic shutdowns and cancellation of public gatherings, as well as the development of clinical methods and the ultimate panacea – an effective vaccine.
Actions taken by countries in regards to testing in the early days appear to have contributed to huge differences down the road. Italy started out with mass testing but then scaled back to only focus on patients who were symptomatic. As the outbreak worsened in Britain, it focused testing and medical resources on critically ill patients.
South Korea and the U.S. reported their first coronavirus cases at almost the same time. But their governments’ attitudes toward testing amid the outbreak couldn’t be more different.
A week after South Korea reported its first case, its health department gathered more than 20 pharmaceutical companies to secure a testing method for COVID-19 that was settled upon eight days later. But weeks after the coronavirus landed in the U.S., there continued to be frustration over shortcomings in diagnostic test distribution and flawed test kits. First there was an outcry over the red tape in getting COVID-19 testing kits approved, then came confusion over who could get a test.
As for travel restrictions, border controls of different types were adopted by many of the six countries. Measures ranged from health checks at the airport to travel warnings and restrictions to quarantining returning overseas travelers. A latecomer to border controls, China didn’t implement restrictions until the end of March when global cases had already exploded.
Such a policy came with extreme measures in certain countries. The Trump administration suspended immigration to the U.S. for 60 days in the name of protecting domestic workers as unemployment hit a record high amid the coronavirus. But this policy left numerous families and businesses reeling instead of boosting employment.
Early-stage border controls also contributed to one problem: Most Western countries neglected prevention and control within their borders.
Restrictions on the movement of peoples within national borders were implemented with varying degrees of effectiveness. Most of the six countries, for instance, adopted stay-at-home orders ahead of lockdowns, except China. In the early morning of January 23, over 20 days after the first known cluster of cases was reported, Wuhan launched a severe lockdown, barring all cars, trains, planes in and out, which lasted 76 days.
In Italy, where similar measures were taken in the country’s northern Lombardy and Veneto – that, combined, makes up 30 percent of the Italian economy, residents were subjected to mandatory home quarantines with all non-essential businesses closed. Meanwhile, some of the other countries like the U.S. and the UK skipped imposing mandatory quarantines in the early stages due to various reasons.
COVID-19 caught the whole world off guard, exposing how we are underprepared in the face of a pandemic of such a scale and scope. The virus has grievously overburdened even the world’s best healthcare systems, with all the seven countries suffering from a dearth of medical professionals and supplies. Doctors and nurses continue to face the danger of being infected, and the psychological burden that they may spread the disease to other patients, or lost their jobs when back from the frontline.
The coronavirus is also not an equal offender — it has disproportionately affected historically marginalized populations. Rates of infection and death from the coronavirus are higher for African and Native Americans, who are on average poorer than their white counterparts. When it comes to age, the elderly makes up a sizable portion of all deaths, due to complications from the coronavirus on top of other conditions. Indigenous peoples are also experiencing higher rates of infection than the national averages of the countries they reside in. In Europe, the Roma live in overcrowded shantytowns, making them particularly affected by the outbreak given the lack of sanitary living conditions.
While outbreaks continue in many of these countries with advanced medical development, the future doesn’t seem to be defined by doom and gloom . Since the outbreak began in January, hundreds of universities, pharmaceutical companies and international organizations have participated in some 320 trials looking into various treatments for COVID-19. Given how divisive COVID-19 has been, the immense scale of this endeavor calls for cooperation across nations, organizations and societies. While time is the best asset for a rapidly spreading pandemic, it is not too late to cultivate this spirit of cooperation.
* The mobile version of the interactive only focuses on six countries for optimal user experience.
Original article: https://news.cgtn.com/news/2020-06-09/Super-Virus-COVID-19-How-we-got-here--Ra9s4L7rBC/index.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20200611005636/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release
Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release
Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
